Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
55.6M
-
Number of holders
-
138
-
Total 13F shares, excl. options
-
46.1M
-
Shares change
-
-298K
-
Total reported value, excl. options
-
$6.42B
-
Value change
-
-$13.1M
-
Put/Call ratio
-
0.23
-
Number of buys
-
72
-
Number of sells
-
-58
-
Price
-
$139.12
Significant Holders of Ascendis Pharma A/S - ADR (ASND) as of Q4 2019
162 filings reported holding ASND - Ascendis Pharma A/S - ADR as of Q4 2019.
Ascendis Pharma A/S - ADR (ASND) has 138 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.1M shares
of 55.6M outstanding shares and own 83.02% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (7.76M shares), FMR LLC (4.77M shares), RA CAPITAL MANAGEMENT, L.P. (4.19M shares), BAKER BROS. ADVISORS LP (3.39M shares), ORBIMED ADVISORS LLC (3.34M shares), Artisan Partners Limited Partnership (2.16M shares), Avoro Capital Advisors LLC (1.87M shares), WELLINGTON MANAGEMENT GROUP LLP (1.72M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.7M shares), and FARALLON CAPITAL MANAGEMENT LLC (1.28M shares).
This table shows the top 138 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.